GILEAD SCIENCES, INC. Fair Value, Measurement with Unobservable Inputs Reconciliation, Recurring Basis, Asset, Gain (Loss) Included in Other Comprehensive Income (Loss) (Deprecated 2012-01-31)
GILEAD SCIENCES, INC. (GILD) reported Fair Value, Measurement with Unobservable Inputs Reconciliation, Recurring Basis, Asset, Gain (Loss) Included in Other Comprehensive Income (Loss) (Deprecated 2012-01-31) of $33.09 million for the 3-month period ending 2012-03-31, per its 10-Q filed 2012-05-04.
Discontinued › Income Statement › Other Income
us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetGainLossIncludedInOtherComprehensiveIncome · last filed 2012-05-04
- GILEAD SCIENCES, INC. fair value, measurement with unobservable inputs reconciliation, recurring basis, asset, gain (loss) included in other comprehensive income (loss) (deprecated 2012-01-31) for the quarter ending 2012-03-31 was $33.09M, a 1432.13% increase year-over-year.
- GILEAD SCIENCES, INC. fair value, measurement with unobservable inputs reconciliation, recurring basis, asset, gain (loss) included in other comprehensive income (loss) (deprecated 2012-01-31) for the quarter ending 2011-12-31 was -$2.00M, a 308.44% decline year-over-year.
- GILEAD SCIENCES, INC. fair value, measurement with unobservable inputs reconciliation, recurring basis, asset, gain (loss) included in other comprehensive income (loss) (deprecated 2012-01-31) for the quarter ending 2011-09-30 was -$22.68M, a 1086.56% decline year-over-year.
- GILEAD SCIENCES, INC. fair value, measurement with unobservable inputs reconciliation, recurring basis, asset, gain (loss) included in other comprehensive income (loss) (deprecated 2012-01-31) for the quarter ending 2011-06-30 was -$7.85M, a 965.82% decline year-over-year.
- GILEAD SCIENCES, INC. fair value, measurement with unobservable inputs reconciliation, recurring basis, asset, gain (loss) included in other comprehensive income (loss) (deprecated 2012-01-31) for fiscal 2011 was -$30.38M, a 704.38% decline from fiscal 2010.
- GILEAD SCIENCES, INC. fair value, measurement with unobservable inputs reconciliation, recurring basis, asset, gain (loss) included in other comprehensive income (loss) (deprecated 2012-01-31) for fiscal 2010 was $5.03M.
| Period end | Fair Value, Measurement with Unobservable Inputs Reconciliation, Recurring Basis, Asset, Gain (Loss) Included in Other Comprehensive Income (Loss) (Deprecated 2012-01-31) 3 month | Fair Value, Measurement with Unobservable Inputs Reconciliation, Recurring Basis, Asset, Gain (Loss) Included in Other Comprehensive Income (Loss) (Deprecated 2012-01-31) 6 month | Fair Value, Measurement with Unobservable Inputs Reconciliation, Recurring Basis, Asset, Gain (Loss) Included in Other Comprehensive Income (Loss) (Deprecated 2012-01-31) 9 month | Fair Value, Measurement with Unobservable Inputs Reconciliation, Recurring Basis, Asset, Gain (Loss) Included in Other Comprehensive Income (Loss) (Deprecated 2012-01-31) 12 month |
|---|---|---|---|---|
| 2012-03-31 | $33.09M 10-Q · filed 2012-05-04 | $31.09M derived: sum of 2 quarters · filed 2012-05-04 | $8.41M derived: sum of 3 quarters · filed 2012-05-04 | $559.00K derived: sum of 4 quarters · filed 2012-05-04 |
| 2011-12-31 | -$2.00M derived: 10-K 12 month − 10-Q 9 month · filed 2012-02-23 | -$24.68M derived: sum of 2 quarters · filed 2012-02-23 | -$32.53M derived: sum of 3 quarters · filed 2012-02-23 | -$30.38M 10-K · filed 2012-02-23 |
| 2011-09-30 | -$22.68M 10-Q · filed 2011-11-04 | -$30.53M derived: sum of 2 quarters · filed 2011-11-04 | -$28.38M 10-Q · filed 2011-11-04 | -$27.41M derived: sum of 4 quarters · filed 2012-05-04 |
| 2011-06-30 | -$7.85M 10-Q · filed 2011-08-05 | -$5.69M 10-Q · filed 2011-08-05 | -$4.73M derived: sum of 3 quarters · filed 2012-05-04 | -$2.43M derived: sum of 4 quarters · filed 2012-05-04 |
| 2011-03-31 | $2.16M 10-Q · filed 2012-05-04 | $3.12M derived: sum of 2 quarters · filed 2012-05-04 | $5.42M derived: sum of 3 quarters · filed 2012-05-04 | $6.33M derived: sum of 4 quarters · filed 2012-05-04 |
| 2010-12-31 | $960.00K derived: 10-K 12 month − 10-Q 9 month · filed 2012-02-23 | $3.26M derived: sum of 2 quarters · filed 2012-02-23 | $4.17M derived: sum of 3 quarters · filed 2012-02-23 | $5.03M 10-K · filed 2012-02-23 |
| 2010-09-30 | $2.30M 10-Q · filed 2011-11-04 | $3.21M derived: sum of 2 quarters · filed 2011-11-04 | $4.07M 10-Q · filed 2011-11-04 | |
| 2010-06-30 | $907.00K 10-Q · filed 2011-08-05 | $1.77M 10-Q · filed 2011-08-05 | ||
| 2010-03-31 | $860.00K 10-Q · filed 2011-05-09 | |||
| 2009-06-30 | $3.27M 10-Q · filed 2010-08-09 | $5.77M 10-Q · filed 2010-08-09 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| AMGEN INC (AMGN) | United States | $219.567B | 22.39 |
| Moderna, Inc. (MRNA) | United States | $77.819B | -8.86 |
| Revolution Medicines, Inc. (RVMD) | United States | $42.805B | -22.69 |
| BIOGEN INC. (BIIB) | United States | $33.427B | 19.60 |
| EXELIXIS, INC. (EXEL) | United States | $14.358B | 16.15 |
| NEUROCRINE BIOSCIENCES INC (NBIX) | United States | $14.131B | 24.25 |
| HALOZYME THERAPEUTICS, INC. (HALO) | United States | $13.083B | 21.59 |
| Twist Bioscience Corp (TWST) | United States | $11.540B | -47.21 |
| BIO-TECHNE Corp (TECH) | United States | $11.379B | 74.68 |
| REPLIGEN CORP (RGEN) | United States | $10.755B | 185.31 |